ArticleJournal of pharmaceutical analysis2025

From foe to friend: Rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor.

Weiming You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.